Bloodless cardiac surgery utilizing a new low-prime oxygenator.
One hundred consecutive patients undergoing open-heart surgery were subjected to a prospective protocol designed for reduction of homologous blood utilization. The main points of this protocol were careful surgical hemostasis, normovolemic hemodilution, and retransfusion of blood lost to the operating field. It included use of the new Bentley BOS-10 Spiraflo oxygenator (Bentley Laboratories, Inc., Irvine, California, U.S.A.). The patients' ages ranged from 6 to 68 years and their weights from 18 to 84 kg. Fifty-four patients were subjected to valvular surgery, 30 to coronary revascularization, 13 to congenital defects repair, and 3 to resection of atrial myxomas. All patients could be weaned from bypass without receiving any blood. Eighty patients completed their surgery, and 60 were discharged from the intensive care unit without receiving any homologous blood or its derivatives. Total blood usage for the series throughout the entire stay in hospital was 1.32 units/patient, which included six reoperations for excessive bleeding. This reduction in blood utilization was achieved without excessive hemodilution and did not produce significant complications.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001803:Blood Transfusion; D001804:Blood Transfusion, Autologous; D006348:Cardiac Surgical Procedures; D002648:Child; D005112:Extracorporeal Circulation; D006400:Hematocrit; D006438:Hemodilution; D006470:Hemorrhage / Q000517:prevention & control*; D006488:Hemostasis, Surgical; D006801:Humans; D008875:Middle Aged; D010106:Oxygenators